Difficulties in differential diagnosis of cutaneous manifestations in patients with coronavirus infection

Patients with severe SARS-CoV-2 infection (COVID-19) and multiple comorbidities should be monitored for possible adverse reactions to prescribed drugs, including drug eruptions (DE) at any stage of treatment. Below, we describe a clinical case of a 92-year-old female patient with severe PCR-confirmed COVID-19. The patient was treated with amoxicillin/clavulanic acid, moxifloxacin, acetylcysteine, and sodium enoxaparin. On day 9 into treatment, the patient developed moderately itching macular rashes showing a tendency to coalesce, but overall showed no signs of deterioration. On day 15, the rashes regressed, following a short course of dexamethasone and chloropyramine. This kind of skin reaction might have been provoked by β-lactams and fluoroquinolones included in the treatment regimen, a secondary bacterial infection, compromised immunity due to advanced age, and high viral load associated with dermatological symptoms. Delayed onset of skin symptoms might be regarded as a marker of COVID-19 severity.

Effective treatment regimen Famotidine with low molecular weight heparin (sodium enoxaparin) severe stages patients COVID-19

Today, according to the scheme enoxaporin sodium 120 mg per day (160 mg)+ Famotidine 80 mg per day were treated more than 300 people they all have objective evidence of the effectiveness of treatment based on a significant decrease in the blood D-dimer! Using the treatment regimen enoxaparin sodium + Famotidine, it is possible to treat patients with COVID-19 in an outpatient setting and prevent hospitalization in hospitals

Influence of low molecular weight heparins on immune system of surgical patients

Venous thromboembolic complications are potentially dangerous complications to life in patients undergoing surgical intervention. The aim of the work is to study the safety of enoxaparin thromboprophylaxis by eliciting the effect of sodium enoxaparin (Flenox) on the immune system of patients undergoing laparoscopic cholecystectomy. Materials and methods. Study group: (n = 15)– patients who were treated with enoxaparin sodium (Flenox) for venous thromboembolic complications. Study of immunograms in patients with calculous cholecystitis was performed before surgery and after two days in post-operative period after appointment of enoxaparin. Results and discussion. In the study group (Flenox), the values of the studied rates did not go beyond the norm. Conclusions. It was established that sodium enoxaparin (Flenox) does not affect the immune system’s rates. In connection with the above mentioned, this medicine can be considered safe and effective for thromboprophylaxis in patients at risk of venous thromboembolism.